

Predictors of Outcome in Pediatric Immune Thrombocytopenic Purpura: Relation to Thrombopoietin Levels

Thesis

*Submitted for Partial Fulfillment of M. Sc. Degree
In Pediatrics*

By

Gina Gergis Abd Elsayed

M.B, B.Ch, 2012

Faculty of Medicine – Ain Shams University

Supervised by

Prof. Dr. Amira Abdel Moneim Adly

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Dr. Fatma Soliman Elsayed Ebeid

Ass. Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Dr. Eman Abdel Rahman Ismail

Consultant of Clinical Pathology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2018

Acknowledgment

First and foremost, I feel always indebted to GOD, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to Prof. Dr. Amira Abdel Moneim Adly, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to Dr. Fatma Soliman Elsayed Ebeid, Assistant Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I wish to introduce my deep respect and thanks to Prof. Dr. Eman Abdel Rahman Ismail, Consultant of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kindness, supervision, great help, active participation, guidance and cooperation in this work.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Ejina Gergis Abd Elsayed

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	iv
List of Abbreviations	vii
Abstract	vii
Introduction	1
Aim of the Work	3
Review of Literature	
Childhood Immune Thrombocytopenia	4
Nomenclature.....	4
Epidemiology.....	5
Pathogenesis	6
Environmental stress	9
Diagnosis	9
Thrombopoietin	41
Clinical application of Thrombopoietin	42
Patients and Methods.....	52
Results	61
Discussion.....	111
Summary	131
Conclusions	136
Recommendations	137
References	138
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	New insights into the pathogenesis of ITP	8
Table (2):	Grading and scoring systems in pediatric ITP	12
Table (3):	Differential diagnosis of thrombocytopenia and suggested tests	17
Table (4):	Comparison of demographic data between ITP patients and controls	62
Table (5):	Descriptive demographic and clinical data of the studied patients with ITP	63
Table (6):	Descriptive disease characteristics of the studied patients with ITP	64
Table (7):	Therapy and outcome of studied ITP patients	66
Table (8):	Laboratory data of the studied ITP patients	68
Table (9):	Comparison between different ITP stages as regards demographic and clinical data	69
Table (10):	Comparison between different ITP stages as regards disease characteristics	71
Table (11):	Comparison between different ITP stages as regards therapy and outcome	73
Table (12):	Comparison between different ITP stages as regards laboratory data	75
Table (13):	Comparison between active ITP and those in remission at time of final assessment (outcome)	78
Table (14):	Comparison between active ITP and those in remission as regards therapy and response	80
Table (15):	Comparison between active ITP and those in remission as regards laboratory data	83

List of Tables (Cont...)

Table No.	Title	Page No.
Table (16):	Comparison between newly diagnosed patients (n=25) who became persistent and those entered in remission after 3 months follow-up as regards disease characteristics.....	86
Table (17):	Comparison between newly diagnosed patients who became persistent and those entered in remission after 3 months follow-up as regards therapy and response (n=25).....	88
Table (18):	Comparison between newly diagnosed patients who became persistent and those entered in remission after 3 months follow-up as regards laboratory data (n=25)	91
Table (19):	Thrombopoietin level between ITP patients compared with healthy controls.....	94
Table (20):	Thrombopoietin levels between newly diagnosed and chronic ITP patients compared with controls	94
Table (21):	Thrombopoietin levels among active ITP and those in remission compared with healthy controls	95
Table (22):	Thrombopoietin levels among newly diagnosed patients who became persistent and those entered in remission after 3 months follow-up compared with healthy controls.....	96
Table (23):	Thrombopoietin levels in relation to clinical characteristics.....	97
Table (24):	Thrombopoietin levels in relation to bleeding manifestations	98
Table (25):	Thrombopoietin levels in relation to clinical characteristics (continuation).....	99
Table (26):	Thrombopoietin levels in relation to therapy and response	100

List of Tables (Cont...)

Table No.	Title	Page No.
Table (27):	Correlation between thrombopoietin and clinical and laboratory data of ITP patients	103
Table (28):	Correlation between thrombopoietin and clinical and laboratory data of newly diagnosed ITP patients.....	105
Table (29):	Correlation between thrombopoietin and clinical and laboratory data of chronic ITP patients	107
Table (30):	Logistic regression analysis for factors contributing to progression to persistent ITP among newly diagnosed patients	110

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Cellular pathogenic mechanisms in ITP	8
Figure (2):	Therapeutic mechanisms of current ITP treatments.	36
Figure (3):	Thrombopoietin receptor activation by TPO or TPO receptor agonists.	45
Figure (4):	Comparison between newly diagnosed and chronic ITP as regards age.	70
Figure (5):	BMI SDS in chronic ITP and newly diagnosed ITP patient.	70
Figure (6):	Comparison between newly diagnosed and chronic ITP patients as regards time from diagnosis to relapse.	74
Figure (7):	Initial platelets at diagnosis in newly diagnosed and chronic ITP patients.	76
Figure (8):	White blood cells at time of assessment among newly diagnosed and chronic ITP patients.	77
Figure (9):	First line therapy among active ITP patients and those in complete remission.	81
Figure (10):	Initial response in active ITP patients and those in complete remission.	82
Figure (11):	Platelets response after 4 weeks in ITP patients who had complete remission and those with active ITP.	84
Figure (12):	Initial lymphocyte count in ITP patients who had complete remission and those with active ITP.	85
Figure (13):	Platelets count at assessment in active ITP patients and those in complete remission.	85

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (14):	Initial response among newly diagnosed ITP patients who had complete remission and those who became persistent ITP after 3 months follow-up.	89
Figure (15):	Second response among newly diagnosed ITP patients who had complete remission and those who became persistent ITP after 3 months follow-up.	90
Figure (16):	Initial platelets count among newly diagnosed ITP patients who had complete remission and those who became persistent ITP after 3 months follow-up.	93
Figure (17):	Platelets count at sampling among newly diagnosed ITP patients who had complete remission and those who became persistent ITP after 3 months follow-up.	93
Figure (18):	Thrombopoietin levels in relation to initial response	102
Figure (19):	Thrombopoietin levels among patients with and without history of relapse (loss of CR or R)	102
Figure (20):	Correlation between thrombopoietin levels and initial platelets count among all the studied ITP patients.....	104
Figure (21):	Correlation between thrombopoietin levels and platelets count at sampling among all the studied ITP patients.....	104

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (22):	Correlation between thrombopoietin levels and initial platelets count among newly diagnosed ITP patients.....	106
Figure (23):	Correlation between thrombopoietin levels and platelets count at assessment among newly diagnosed ITP patients.	106
Figure (24):	Correlation between thrombopoietin levels and initial absolute lymphocyte count among chronic ITP patients.	108
Figure (25):	Correlation between thrombopoietin levels and hemoglobin level among chronic ITP patients.	108
Figure (26):	Correlation between thrombopoietin levels and initial platelets count among chronic ITP patients.	109
Figure (27):	Correlation between thrombopoietin levels and platelets count at assessment among chronic ITP patients.	109

List of Abbreviations

Abb.	Full term
<i>Anti-dsDNA</i>	<i>Anti double stranded DNA</i>
<i>ASH</i>	<i>American society of hematology</i>
<i>BMI SDS</i>	<i>Body mass index standard deviation score</i>
<i>c-Mpl</i>	<i>Myeloproliferative leukemia protein</i>
<i>CMV</i>	<i>Cytomegalovirus</i>
<i>CR</i>	<i>Complete response</i>
<i>CVID</i>	<i>Combined variable immunodeficiency</i>
<i>ELISA</i>	<i>enzyme -linked immunosorbent assay</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>HBV</i>	<i>Hepatitis B virus</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>
<i>HSC</i>	<i>hematopoietic stem cell</i>
<i>ICH</i>	<i>Intracranial hemorrhage</i>
<i>ITP</i>	<i>Immune thrombocytopenia</i>
<i>IVIG</i>	<i>Intravenous immunoglobulins</i>
<i>IWG</i>	<i>International Working Group</i>
<i>MKs</i>	<i>Megakaryocytes</i>
<i>MF</i>	<i>Myelofibrosis</i>
<i>MAIPA</i>	<i>Monoclonal antibody-specific immobilization of platelet antigen</i>
<i>MPV</i>	<i>mean platelet volume</i>
<i>NSAIDS</i>	<i>Non steroidal antiinflammatory drugs</i>
<i>R</i>	<i>Response</i>
<i>TPO</i>	<i>Thrombopoietin</i>
<i>TPO-RA</i>	<i>Thrombopoietin receptor analogues</i>
<i>VNN1</i>	<i>Vanin-1</i>

Abstract

Background: Immune thrombocytopenia (ITP) is one of the most common bleeding disorders in children. It is not easy to predict the course of the disease at the time of initial diagnosis. Measurement of thrombopoietin levels may help distinguish between various causes of thrombocytopenia and predict treatment response to thrombopoietin receptor agonists. Some studies investigated predictors of outcome in ITP but these were retrospective studies and to our knowledge, no prospective studies in children with ITP. **Aim:** This prospective study aimed to investigate the clinical features of immune thrombocytopenia in children and adolescents and predictors of outcome including the diagnostic potential of thrombopoietin levels as well as role in predicting response to therapy. **Methods:** Seventy pediatric patients with ITP; 25 were newly diagnosed patients, 45 had chronic ITP. They were compared with 20 age- and sex-matched healthy controls. Patients were studied stressing on bleeding manifestations, organomegaly/lymphadenopathy and therapy. Bleeding score was calculated to each patient according to the ITP Bleeding Scale (IBLS). Complete blood count was done serum levels of thrombopoietin were assessed by enzyme linked immunosorbent assay. The 25 patients with newly diagnosed ITP were followed-up for 3 months. The response after each line of treatment was recorded. **Results:** The incidence of epistaxis and bleeding with hypotension were higher in chronic ITP patients than newly diagnosed ITP patients. Initial platelets count at diagnosis was significantly higher in chronic ITP than newly diagnosed ITP patients. Age of onset > 5 years as well as the incidence of no recovery after 4 weeks of diagnosis and menorrhagia was significantly higher in active ITP patients than those in complete remission. It was found that 9 out of 25 (36.0%) patients had persistent ITP after 3 months follow-up and all were in active condition compared with those who entered in remission. Comparison between newly diagnosed patients who entered in complete remission and who became persistent after 3 months follow-up showed that age of onset > 5 years old was associated with progression to persistent ITP. Intake of IVIG was more frequent among newly diagnosed ITP patients who entered in complete remission although the difference did not reach a significant level. Initial platelet count at diagnosis was significantly higher in persistent ITP than those who had remission while platelets count 4 weeks after diagnosis was significantly lower. As regards thrombopoietin levels, no significant difference was found between all

ITP patients and controls or between newly diagnosed and chronic ITP patients. High thrombopoietin levels have been noticed among those in active ITP. Thrombopoietin levels were significantly higher among patients with persistent ITP than those who had complete remission. Thrombopoietin level was significantly different in relation to initial response where highest levels were found among patients who had no response. ITP patients who experienced loss of response (relapse) had higher thrombopoietin levels. Thrombopoietin levels were inversely related to platelets count. **Conclusions:** The predictors of progression to persistent ITP and chronicity among our pediatric patients with ITP were age of onset > 5 years old, high initial platelet count, low platelets count 4 weeks after diagnosis and high baseline thrombopoietin levels. High baseline thrombopoietin levels were also associated with absence of initial response as well as loss of response (relapse) denoting a poor clinical outcome. Therefore, it is important to be incorporated in routine practice for ITP patients to predict therapeutic response and modify treatment regimen, accordingly. Further prospective studies with longer follow-up including larger number of newly diagnosed ITP patients to verify our results and investigate predictors of chronicity in childhood ITP.

INTRODUCTION

Childhood immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia (peripheral blood platelet count $<100 \times 10^9/L$). ITP is one of the most common bleeding disorders in children, with an incidence of approximately four per 100.000 per year (*Labarque and Van Geet, 2014; Roganović, 2015*).

ITP most frequently presents with acute onset of purpura and bruising in an otherwise healthy child, often after a preceding mild viral infection. A benign and self-limited course is common, and major bleeding complications are exceptional (*Bussel, 2013*). The management including diagnostic investigations, treatment and follow-up is controversial (*Kühne and Imbach, 2013*).

International Working Group (IWG) of both pediatric and adult experts in ITP defined three different phases of ITP: “newly diagnosed ITP” (ITP within 3 months from diagnosis), “persistent ITP” (ongoing ITP between 3 and 12 months from diagnosis), and “chronic ITP” (ITP lasting more than 12 months). Severity of ITP is based on the presence of bleeding signs rather than the degree of thrombocytopenia. The term “severe ITP” should be used only in patients with clinically relevant bleeding, which is defined as bleeding at presentation sufficient to mandate treatment, or occurrence of new bleeding symptoms requiring additional therapeutic intervention or increase in drug dose (*Rodeghiero et al., 2009*).

ITP has a strikingly different clinical course in adults and children. Spontaneous remission in adults with ITP is less frequent and majority develops chronic ITP (*Cines and Blanchette, 2002*). Children, on the other hand, have a much more favorable prognosis. In more than 75%, the disease resolves within 6 months irrespective of treatment (*George et al., 1996*).

In children, however, it is not possible to predict the course of the disease at the time of initial diagnosis. Thrombopoietin (TPO) is the major regulator of platelet production. Prior studies in animal models (*Kuter and Rosenberg, 1994; Wendling et al., 1994*) and in humans (*Nichol et al., 1995*) have demonstrated that TPO levels vary inversely with circulating platelet mass. Additional clinical studies have suggested that TPO levels also vary inversely with the rate of megakaryopoiesis (*Chang et al., 1996; Yamazaki et al., 2006*). Thus, measurement of serum TPO levels may help distinguish between various causes of thrombocytopenia and predict treatment response to TPO receptor agonists (*Makar et al., 2013*).

One prospective study involved a cohort of adult patients presenting with a newly diagnosed episode of ITP described the clinical features of adult ITP and its evolution over a 12-month period and explored the baseline predictors of chronicity (*Grimaldi-Bensouda et al., 2016*). However, to our knowledge, no such prospective studies in children with ITP.

AIM OF THE WORK

The aim of this study is to investigate the clinical features of immune thrombocytopenia in children and adolescents and to explore predictors of outcome including the diagnostic potential of thrombopoietin levels as well as its role in predicting response to therapy.